system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
72 13.10 English Language. 72 13.11 Equitable Relief. 72 13.12 Waiver and Non-Exclusion of Remedies. 72 13.13 No Benefit to Third Parties. 72 13.14 Further Assurance. 73 13.15 Relationship of the Parties. 73 13.16 Performance by Affiliates. 73 13.17 Counterparts; Facsimile Execution. 73 13.18 References. 73 13.19 Schedules. 73 13.20 Construction. 73 SCHEDULES Schedule 1.84 Initial Development Plan Schedule 1.99 Licensed Compound Schedule 3.7 Pre-Approved Third Party Providers Schedule 10.2 Disclosure Schedules Schedule 10.2.1 Existing Patents Schedule 13.7.3 Arbitration - iii - Source: HARPOON THERAPEUTICS, INC., 10-K, 3/12/2020 DEVELOPMENT AND OPTION AGREEMENT This Development and Option Agreement (the "Agreement") is made and entered into effective as of November 20, 2019 (the "Effective Date") by and between Harpoon Therapeutics, Inc., a Delaware corporation ("Harpoon"), and AbbVie Biotechnology Ltd, a Bermuda corporation ("AbbVie"). Harpoon and AbbVie are sometimes referred to herein individually as a "Party" and collectively as the "Parties." RECITALS WHEREAS, Harpoon Controls (as defined herein) certain intellectual property rights with respect to the Licensed Compound (as defined herein) and Licensed Products (as defined herein) in the Territory (as defined herein); and WHEREAS, Harpoon wishes to grant an option to a license to AbbVie, and AbbVie wishes to take, such option to a license under such intellectual property rights to develop and commercialize Licensed Products in the Territory, in each case in accordance with the terms and conditions set forth below. NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: ARTICLE 1 DEFINITIONS Unless otherwise specifically provided herein, the following terms shall have the following meanings: 1.1 "AbbVie" has the meaning set forth in the preamble hereto. 1.2 [***] has the meaning set forth in [***] 1.3 [***] has the meaning set forth in [***]. 1.4 [***] has the meaning set forth in [***] 1.5 [***] has the meaning set forth in [***]. 1.6 "AbbVie [***] Rights" has the meaning set forth in Section 5.9.2. 1.7 "AbbVie Indemnitees" has the meaning set forth in Section 11.2. 1.8 "AbbVie Know-How" means all Information that is (a) Controlled by AbbVie or any of its Affiliates during the Term, (b) developed or acquired by AbbVie or any of its Affiliates during the Term as a result of performance under this Agreement, (c) not generally known and (d) necessary or reasonably useful for the Exploitation of the Licensed Compound or a Licensed Product, but excluding any Joint Know-How or Information published in any AbbVie Patents or Joint Patents. 1.9 "AbbVie Patents" means all of the Patents that (a) are Controlled by AbbVie or any of its Affiliates during the Term, (b) claim inventions made or conceived by or on behalf of AbbVie or any of its Affiliates during the Term as a result of performance under this Agreement, and (c) are necessary or reasonably useful (or, with respect to patent applications, would be necessary or reasonably useful if such Source: HARPOON THERAPEUTICS, INC., 10-K, 3/12/2020 patent applications were to issue as patents) for the Exploitation of the Licensed Compound or a Licensed Product, but excluding any Joint Patents. 1.10 "AbbVie Reversion IP" has the meaning set forth in Section 12.7.1. 1.11 "AbbVie Withholding Tax Action" has the meaning set forth in Section 6.8.2. 1.12 "Acceptance" means, with respect to a Drug Approval Application, receipt of written notice from the applicable Regulatory Authority indicating that such Drug Approval Application has been accepted for filing and further review. 1.13 "Accounting Standards" means, with respect to a Party, that such Party shall maintain records and books of accounts in accordance with United States Generally Accepted Accounting Principles. 1.14 "Acquisition" means, with respect to a Party, a merger, acquisition (whether of all of the stock or all or substantially all of the assets of a Person or any operating or business division of a Person) or similar transaction by or with the Party, other than a Change in Control of the Party. 1.15 "Adverse Ruling" has the meaning set forth in Section 12.2.1. 1.16 "Affiliate" means, with respect to a Party, any Person that, directly or indirectly, through one (1) or more intermediaries, controls, is controlled by or is under common control with such Party. For purposes of this definition, "control" and, with correlative meanings, the terms "controlled by" and "under common control with" means (a) the possession, directly or indirectly, of the power to
"""

Extract the exact clause related to "Agreement Date" from the excerpt above.